In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Protara Therapeutics (TARA – Research Report), with a price target of $22.00.
Charles Zhu has given his Buy rating due to a combination of factors surrounding Protara Therapeutics’ promising developments with TARA-002 in the treatment of non-muscle invasive bladder cancer (NMIBC). The company has shown encouraging results in early clinical trials, particularly with BCG-unresponsive patients, where a complete response rate of 100% was observed at the six-month mark in a small cohort. This suggests a strong potential for TARA-002 to be a competitive player in the NMIBC therapeutic landscape.
Furthermore, Protara Therapeutics is expected to provide significant clinical updates by mid-2025, which could further validate the efficacy of TARA-002. The management’s confidence in achieving competitive complete response rates, along with their strategic focus on enrolling more BCG-unresponsive patients, underscores the potential for TARA-002 to achieve best-in-class status. These factors, combined with the company’s solid financial position, contribute to the high conviction in the stock’s potential upside, justifying the Buy rating.
According to TipRanks, Zhu is an analyst with an average return of -13.8% and a 30.00% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Merus, Mersana Therapeutics, and Nuvalent.